MD-18(Radella Pharmaceuticals)

N/A

Report date: 2024/11/11 17:56:47
NME

Base Information

Drug NameMD-18(Radella Pharmaceuticals)
Drug Alias NameMD-18(Radella Pharmaceuticals)MD18(Radella Pharmaceuticals)
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionProtein-tyrosine phosphatase 1B inhibitors
TargetsProtein-tyrosine phosphatase 1B
Therapy Area/IndicationsObesityDiabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRadella Pharmaceuticals LLC
China Registration ClassN/A

Develop Information

Active CompaniesRadella Pharmaceuticals LLC
Inactive CompaniesN/A
Active IndicationsObesityDiabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A